ClearPoint Neuro reports preliminary Q4 revenue $5.2M, up 21% year-over-year

Increased biologics and drug delivery revenue to $2.3M, a 37% year-over-year increase; Increased functional neurosurgery products and services to $2.3M, a 7% year-over-year increase; Cash burn of approximately $3M in the fourth quarter. The Company had approximately $37.5M in cash, cash equivalents and short-term investments at December 31, 2022. Full Year 2022 Preliminary Unaudited Financial Highlights: Achieved preliminary unaudited record revenue of $20.6M, a 26% year-over-year increase, versus most recent guidance of $21.0 – $22M; Increased biologics and drug delivery revenue to $9.1M, a 34% year-over-year increase; Increased functional neurosurgery products and services revenue to $9.1M, a 13% year-over-year increase; Added multiple new biologics and drug delivery partners in the year to bring the total to more than 50 partners.